These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 26780190)

  • 21. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
    Chen L; Silapunt S; Migden MR
    Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
    Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vismodegib for Locally Advanced Basal Cell Carcinoma: Descriptive Analysis of a Case Series and Comparison to the Literature.
    Viscusi KS; Hanke CW
    J Drugs Dermatol; 2015 Sep; 14(9):956-62. PubMed ID: 26355613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
    Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
    Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma.
    Burness CB; Scott LJ
    Target Oncol; 2016 Apr; 11(2):239-46. PubMed ID: 26867946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sonidegib phosphate: new approval for basal cell carcinoma.
    Tibes R
    Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
    Frampton JE; Basset-Séguin N
    Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 37. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.
    Mohan SV; Chang AL
    Semin Cutan Med Surg; 2014 Jun; 33(2):68-71. PubMed ID: 25085664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
    Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 40. Vismodegib: a review.
    Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
    Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.